Liraglutide treatment improves postprandial lipid metabolism and cardiometabolic risk factors in humans with adequately controlled type 2 diabetes: A single‐centre randomized controlled study

AIMS: Patients with type 2 diabetes and non‐alcoholic fatty liver disease (NAFLD) exhibit considerable residual risk for cardiovascular disease (CVD). There is, therefore, increasing interest in targeting postprandial lipid metabolism and remnant cholesterol. Treatment with the glucagon‐like peptide...

Descripción completa

Detalles Bibliográficos
Autores principales: Matikainen, Niina, Söderlund, Sanni, Björnson, Elias, Pietiläinen, Kirsi, Hakkarainen, Antti, Lundbom, Nina, Taskinen, Marja‐Riitta, Borén, Jan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6585708/
https://www.ncbi.nlm.nih.gov/pubmed/30073766
http://dx.doi.org/10.1111/dom.13487

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6585708/
https://www.ncbi.nlm.nih.gov/pubmed/30073766
http://dx.doi.org/10.1111/dom.13487

Ejemplares similares